Mohammed Khan, MD
Cardiovascular Disease · Springfield, OHNPI 1144218025
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,180 of the $2,900 with a category attached, or 75.2%. 24 manufacturers reported payments, led by Janssen Research & Development, LLC at 34.8% of the total. Reporting peaked in 2023 at $1,281 and has fallen 60.4% since, to $508 in 2025.
Across 82 payments — averaging $35.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$1K
- Johnson & Johnson$245
- United Therapeutics Corporation$224
- Boston Scientific$208
- Novartis$193
- Medtronic$161
- plus $860 from 18 others
Across 10 payments — averaging $2036.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$17K
- AbbVie$3K
What the payments were for
- Travel & lodging$72025%
- Food & beverage$2,18075%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 8 | $1,010 |
| Johnson & Johnson | 10 | $245 |
| United Therapeutics Corporation | 7 | $224 |
| Boston Scientific | 6 | $208 |
| Novartis | 11 | $193 |
| Medtronic(2 entities) | 2 | $161 |
| Amgen | 9 | $128 |
| Janssen Scientific Affairs, LLC | 1 | $100 |
| Regeneron Healthcare Solutions, Inc. | 5 | $83 |
| Surmodics, Inc. | 1 | $77 |
| Amarin Pharma, Inc. | 3 | $52 |
| E.r. Squibb & Sons, L.L.C. | 2 | $47 |
| Stryker | 1 | $47 |
| Cvrx, Inc. | 2 | $46 |
| Daiichi Sankyo Inc. | 3 | $42 |
| Pfizer | 2 | $40 |
| Actelion Pharmaceuticals US, Inc. | 2 | $38 |
| Boehringer Ingelheim | 1 | $32 |
| Kestra Medical Technology Services, Inc. | 1 | $30 |
| Bayer | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Abiomed | 1 | $20 |
| Merck | 1 | $19 |
| Vital Connect, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$220
How this compares
$2,900 in reported general payments places this provider in the 65th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 331 | $323,729 |
| XareltoRivaroxaban | 192 | $195,627 |
| EntrestoSacubitril/Valsartan | 29 | $45,924 |
| Repatha SureclickEvolocumab | 58 | $41,709 |
| JardianceEmpagliflozin | 29 | $28,544 |
| Praluent PenAlirocumab | 12 | $12,042 |
| Atorvastatin Calcium | 747 | $10,721 |
| VascepaIcosapent Ethyl | 24 | $8,493 |
| Dofetilide | 16 | $7,588 |
| Amiodarone Hcl | 136 | $6,260 |
| Metoprolol Succinate | 353 | $5,007 |
| Rosuvastatin Calcium | 177 | $4,222 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 76 | $3,697 |
| Ranolazine ErRanolazine | 48 | $2,703 |
| Ezetimibe | 107 | $2,677 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $40 | $323,729331 claims |
| Johnson & JohnsonXarelto | $245 | $195,627192 claims |
| NovartisEntresto | $193 | $45,92429 claims |
| Boehringer IngelheimJardiance | $32 | $28,54429 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 827 cardiovascular disease providers in Ohio.
Other cardiovascular disease in Springfield
- Guilherme AttizzaniCleveland$1.3M
- Gregory LamCircleville$428K
- Emil HayekHudson$379K
- Abraham LincoffCleveland$369K
- Oussama WazniCleveland$367K
- Ian NeelandCleveland$329K
- Kamal ShemisaCincinnati$314K
- Mehdi ShishehborElyria$237K
- Abdu HawwaGarfield Hts$234K
- Jayanta MukherjeeColumbus$227K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.